GOOG stock rises as Greenland tariff jitters ease — what to watch before Alphabet earnings
21 January 2026
2 mins read

GOOG stock rises as Greenland tariff jitters ease — what to watch before Alphabet earnings

New York, Jan 21, 2026, 10:16 EST — Regular session

  • Alphabet Class C shares (GOOG) rose roughly 1% in early trading
  • Markets rebound while processing Trump’s comments at Davos and renewed tariff warnings
  • Attention shifts to Alphabet’s early-February earnings for clues on advertising and cloud performance

Alphabet Inc’s Class C shares (GOOG), which carry no voting rights, gained roughly 1% Wednesday, helping lift the Google parent amid a tentative big tech bounce. The stock climbed $3.17 to trade at $325.33 in early trading.

This matters since Alphabet ranks among the market’s heavy hitters. When headlines on trade or policy drop, traders tend to jump on the biggest, most liquid tech stocks right away, then figure out the details afterward.

This week served as a reminder. Much of the price movement isn’t driven by Google search trends or YouTube performance on any single day, but rather by investors’ appetite for “risk” and its scale.

U.S. stocks inched higher in volatile trading after President Donald Trump, speaking at Davos, ruled out using force to acquire Greenland. Still, investors stayed cautious over the risk of renewed trade tensions. “That likely put a floor in the recent sell-off,” said Art Hogan, chief market strategist at B Riley Wealth, but he warned markets remain “concerned about reigniting a trade war.” Reuters highlighted a busy slate of upcoming U.S. data, including GDP, PMI readings, and the PCE price index, the Fed’s favored inflation gauge. 1

Markets tumbled the day before after Trump threatened new tariffs on European allies unless the U.S. gets to buy Greenland. Wasif Latif, CIO at Sarmaya Partners, described it as a “pretty significant risk-off day,” noting that geopolitical risks are back in focus. A Reuters wrap reported that European leaders plan to meet Thursday in Brussels for an emergency summit to discuss possible retaliation, including tariffs totaling 93 billion euros ($109 billion). 2

Alphabet made headlines at Davos, but the news didn’t move its stock. Isomorphic Labs, the AI drug discovery startup supported by Google, now aims to start clinical trials by the end of 2026, CEO and founder Demis Hassabis revealed—marking a delay from previous plans. 3

Regulation remains a persistent factor, unlikely to disappear. Australia has already banned social media access for under-16s. Other nations are considering similar age restrictions that could impact platforms like Alphabet’s YouTube and Meta’s Instagram and Facebook. 4

Alphabet investors face a clear near-term picture: ad demand usually mirrors business confidence, and cloud spending can drop sharply if companies grow cautious. When the macro environment sours, these are the first areas to raise concern.

The downside is straightforward. Should tariff threats turn into real levies and provoke retaliation, the “risk-off” mood that weighed on megacap tech earlier this week could reemerge. And GOOG won’t be immune, even with its solid fundamentals.

Alphabet’s next big moment isn’t a speech but a calendar date: the company will reveal its fourth-quarter and full-year results on Feb. 4 at 4:30 p.m. ET. This report could shake up what investors expect on ads, cloud, and spending heading into 2026. 5

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Grab stock slips after Tuesday pop as BofA turns bullish; earnings date looms
Previous Story

Grab stock slips after Tuesday pop as BofA turns bullish; earnings date looms

Sandisk stock price jumps again after Citi lifts target to $490; SNDK earnings next week in focus
Next Story

Sandisk stock price jumps again after Citi lifts target to $490; SNDK earnings next week in focus

Go toTop